Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of tegavivint in treating
patients with large b-cell lymphomas that has come back (relapsed) or does not respond to
treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Giving tegavivint may help control the disease.